Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Mar 20, 2007
filing date -
Oct 20, 1992
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Pharmaceutical compositions containing oxandrolone and a pharmaceutically acceptable carrier are provided for ameliorating myopathy, weight loss or muscle wasting resulting from human immunodeficiency virus type-1 infection, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams or more.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully